Summit Therapeutics' Ivonescimab Shows Strong Survival Benefits in NSCLC Trials — Summit Therapeutics Inc.

Event summary

Summit Therapeutics reported positive overall survival data for ivonescimab in the HARMONi-6 trial, showing a hazard ratio of 0.66 compared to tislelizumab in squamous NSCLC.
The FDA has set a PDUFA goal action date of November 14, 2026, for Summit's BLA seeking approval for ivonescimab in combination with chemotherapy for EGFR-mutated NSCLC.
Summit raised $230.8 million in gross proceeds through its ATM facility during Q2 2026 and an additional $68.4 million subsequent to June 2026.
The company sold ridinilazole, an investigational Phase III precision antibiotic asset, to Biossil for $500,000 upfront and up to $104.5 million in milestones.

The big picture

Summit Therapeutics' positive data for ivonescimab in NSCLC trials positions it as a potential leader in the immuno-oncology field, particularly with its bispecific PD-1/VEGF antibody approach. The company's strategic partnerships and recent fundraising efforts underscore its commitment to advancing this therapy across multiple tumor types. The upcoming FDA decision on ivonescimab will be a critical milestone in determining the company's future trajectory.

What we're watching

Regulatory Approval: Whether the FDA will approve ivonescimab by the November 14, 2026 PDUFA date based on the submitted data.
Clinical Development: The pace at which Summit can expand its global clinical development program for ivonescimab into additional tumor types and settings.
Financial Strategy: How Summit will allocate the proceeds from its recent fundraising and asset sale to support ongoing clinical trials and operational expansion.